The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | What is the future for AML patients who cannot be treated with current therapy?
Shyamala Navada, MD, from Tisch Cancer Institute, New York, NY, US, discusses what the results from the Phase I/II trial evaluating the effectiveness of oral rigosertib in combination with azacitidine for the treatment of acute myeloid leukemia (AML) (NCT01926587) represents in terms of future treatments for AML. Here, she explains that this combination regimen may become a new therapeutic option for elderly AML patients who cannot tolerate standard induction therapies, as well as those with myelodysplastic syndrome (MDS). This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
